Declaration of conflict of interest: No conflict of interest.
Juvenile idiopathic arthritis in the new world of biologics
Article first published online: 6 MAY 2013
© 2013 The Authors. Journal of Paediatrics and Child Health © 2013 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 49, Issue 9, pages E405–E412, September 2013
How to Cite
Ostring, G. T. and Singh-Grewal, D. (2013), Juvenile idiopathic arthritis in the new world of biologics. Journal of Paediatrics and Child Health, 49: E405–E412. doi: 10.1111/jpc.12218
- Issue published online: 5 SEP 2013
- Article first published online: 6 MAY 2013
- Manuscript Accepted: 18 NOV 2012
- biological drugs;
- intra-articular steroid injections;
- juvenile idiopathic arthritis;
- multidisciplinary team;
Juvenile idiopathic arthritis results in significant pain and disability in both children and adults. Advances in treatment resulting in improved long-term outcomes have occurred; however, an emphasis on early and aggressive diagnosis and management hopes to improve outcomes further. Juvenile idiopathic arthritis remains a clinical diagnosis of exclusion, but further research may delineate biological markers associated with the disease and its subtypes. Therapy for patients includes intra-articular steroid injections, disease modifying agents such as methotrexate and biological agents. Biological agents have provided exciting new therapeutic options in the last decade; however, long-term side effects of modulating the immune system are not yet fully understood. Systemic steroids may also be required but their long-term use is avoided. Uveitis needs to be screened for in all of those with the diagnosis. Multidisciplinary team care is required in managing these young people.